Dihexa was developed as a structurally modified analogue of angiotensin IV and retains key features of the parent scaffold while incorporating modifications designed to alter physicochemical and pharmacological properties
Targeted Therapy and Investigational Approaches No targeted therapy has been approved for MPNST as of 2025
TB-500 (Thymosin -4 fragment) The classic regenerative combination
N-acetylcysteine Oxidative stress is thought to cause many of the clinical signs and symptoms of sleep apnea, including cardiovascular, neurological, and immune dysfunction
Oxid Med Cell Longev 2013:956792 Pradhan S, Bonekamp S, Gillen JS et al (2015) Comparison of single voxel brain MRS AT 3T and 7T using 32-channel head coils
Our goal is to ensure that your treatment remains safe, effective, and aligned with your wellness goals